For several years, docetaxel was the only treatment shown to improve survival of patients
with metastatic castration‐resistant prostate cancer (mCRPC). There are now several novel …

Objective: We performed a systematic review of the literature to assess the efficacy and the
safety of second-line agents targeting metastatic castration-resistant prostate cancer …

Background/Aim: Docetaxel has been widely used in metastatic Castration-resistant
Prostate Cancer (mCRPC) patients for decades. The purpose of the study was to evaluate …

This Practice point commentary discusses the findings of a randomized, multicenter, report
published by Berthold et al, in which the results of the pivotal TAX 327 study are updated …

Purpose The purpose of the study was to define clinical factors for successful treatment
response and re-exposure to docetaxel in metastatic castration-resistant prostate cancer …

Background Satraplatin is an oral platinum compound that has demonstrated efficacy and
tolerability in prostate cancer. Preclinical synergy between bevacizumab and platinum has …

4526^ Background: The Phase III TROPIC trial showed that cabazitaxel plus prednisone
(CbzP) significantly improved overall survival (OS) compared with mitoxantrone plus …

Background Systemic therapy options are limited for metastatic castration-resistant prostate
cancer (CRPC) patients who progress following docetaxel (Taxotere). This phase II trial …

Background Activation of the PI3K-Akt-mTOR signaling pathway is common in advanced
castration resistant prostate cancer (CRPC), typically through PTEN loss. Preclinical studies …

Results: Front line cytotoxic therapy consists of docetaxel combined with prednisone. In two
randomized trials, docetaxel based therapy demonstrated a 20%-24% improvement in …